Celltrion signs agreement for atherosclerosis drugs development
Celltrion, a leading biopharmaceutical company headquartered in Incheon,
Korea has signed an Incubation agreement with Emory University in Atlanta to support the research and development of new drug candidates for atherosclerosis. Under the agreement, Celltrion will share its accumulated biologics development expertise with Emory University School of Medicine and the Wallace H. Coulter Department of Biomedical Engineering at Emory University and Georgia Institute of Technology, and provide research costs and manufacturing materials of new drug candidates for atherosclerosis. Celltrion will have a preferential right to acquire a license for inventions resulting from the agreement.